Literature DB >> 3662567

Subcutaneous phaeohyphomycosis caused by Exserohilum rostratum in an immunocompetent host.

G E Burges1, C T Walls, J C Maize.   

Abstract

A healthy, 55-year-old woman developed a subcutaneous abscess and systemic symptoms of nausea, dizziness, and chills following minor trauma to her leg. Histopathologic examination of a skin biopsy specimen revealed golden-brown colored mycelial elements, and culture resulted in growth of a dematiaceous fungus identified as Exserohilum rostratum. Surgical excision of the abscess and concomitant oral therapy with ketoconazole resulted in resolution of symptoms. In previously reported cases of human phaeohyphomycosis caused by Exserohilum and related Bipolaris species in both immunocompromised and immunocompetent hosts, treatment has varied from topical antimicrobial therapy to combined surgery and intravenous antifungal chemotherapy. Our experience leads us to believe that surgical débridement of an accessible focus of infection along with orally administered ketoconazole may provide adequate therapy in an immunocompetent host.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662567

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  4 in total

Review 1.  Black Molds and Melanized Yeasts Pathogenic to Humans.

Authors:  Anuradha Chowdhary; John Perfect; G Sybren de Hoog
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

2.  Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia.

Authors:  Maude Saint-Jean; Guy St-Germain; Céline Laferrière; Bruce Tapiero
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-05       Impact factor: 2.471

3.  Extensive Exserohilum infection in a burn patient.

Authors:  Richard R Jahan-Tigh; Megan Shelton; Ronald Rapini
Journal:  JAAD Case Rep       Date:  2015-06-10

Review 4.  Exserohilum: an emerging human pathogen.

Authors:  A Adler; I Yaniv; Z Samra; J Yacobovich; S Fisher; G Avrahami; I Levy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.